Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Myeloproliferative Disorders 2Anemia 2Primary Myelofibrosis 1Myelodysplastic Syndromes 1

Interventions

fludarabine 19Cyclophosphamide 19fludarabine phosphate 16Azacitidine 14Tacrolimus 13Melphalan 13venetoclax 10Cytarabine 10Busulfan 10Whole-Body Irradiation 9Thiotepa 9Mycophenolic Acid 9Stem Cell Transplantation 7Peripheral Blood Stem Cell Transplantation 7Decitabine 7decitabine and cedazuridine drug combination 6Methotrexate 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Sirolimus 5CPX-351 5AP 1903 reagent 5thymoglobulin 4Vorinostat 4Mesna 4Injections 4Daunorubicin 4Biopsy 4Ipilimumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic Syndromes × luspatercept × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡